INCB 01158-206 (#1151)
Laufzeit: 01.01.2019 - 31.12.2040
Kurzfassung
A Randomized Open Label Phase 1/2 Study of INCB001158
Combined With Subcutaneous (SC) Daratumumab, Compared To Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma
